Increased occurrence of left ventricular thrombi during early treatment with timolol in patients with acute myocardial infarction.
To examine whether early intervention with timolol influences the occurrence of left ventricular thrombi in acute anterior myocardial infarction, 40 patients with acute anterior myocardial infarction admitted to hospital within 6 hr of onset of symptoms were randomly assigned to receive intravenous followed by oral timolol maleate or placebo. Five (25%) of 20 patients in the placebo group and 14 (73.7%) of 19 patients with confirmed infarction in the timolol group developed a left ventricular apical thrombus as detected by two-dimensional echocardiography from 2 to 10 days after inclusion (p less than .005). Patients received anticoagulants only after a left ventricular thrombus had been diagnosed. Only one patient with thrombus suffered peripheral embolization (timolol group). The treatment groups were comparable with respect to location of regional left ventricular dysfunction, electrocardiographic changes, and infarct size estimated by creatine kinase release. However, computer-assisted regional wall motion analysis demonstrated significantly reduced apical wall motion in the timolol group compared with the placebo group (p less than .01). Also, the mean heart rate during the first 10 days after the acute infarction was reduced by 13% in the timolol group (p less than .001). The reduction in heart rate and left ventricular apical wall motion caused by timolol in patients with acute anterior myocardial infarction may increase the occurrence of left ventricular thrombi.
D003402:Creatine Kinase / Q000097:blood; D004311:Double-Blind Method; D004341:Drug Evaluation; D004452:Echocardiography; D006331:Heart Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology*; D006352:Heart Ventricles / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D011897:Random Allocation; D013599:Systole / Q000187:drug effects; D013927:Thrombosis / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology*; D013997:Time Factors; D013999:Timolol / Q000009:adverse effects*; D014859:Warfarin / Q000627:therapeutic use
D014859:Warfarin; D013999:Timolol; D003402:Creatine Kinase